Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects

Hypertension

Volumn 47, Issue 4, 2006, Pages 771-777

  Smith, Ronald D ^a   Levy, Pavel ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Cardiac output; Hemodynamics; Hypertension, arterial; Hypertension, essential; Vascular resistance

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; IMPEDANCE CARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONITOR; MULTICENTER STUDY; NON INVASIVE MEASUREMENT; PATHOGENESIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; SYSTOLE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOGRAPHY, IMPEDANCE; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SYSTOLE; VASCULAR RESISTANCE;

EID: 33645802371     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000209642.11448.e0     Document Type: Article

References (37)

1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
3. Chery DK, Woodwell DA. National Ambulatory Care Medical Survey: 2000 summary. Advance Data. 2002;328:1-32.
4. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Texas: American Heart Association; 2003.
5. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004;164:2126-2134.
6. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151:1786-1792.
7. Ferrario CM, Page IH. Current views concerning cardiac output in the genesis of experimental hypertension. Circ Res. 1978;43:821-831.
8. Davidson RC, Ahmad S. Hemodynamic profiles in essential and secondary hypertension. In: Izzo JL, Black HR, eds. Hypertension Primer. 3rd ed. Dallas, TX: Council on High Blood Pressure Research, American Heart Association; 2003:349-351.
9. Sullivan JM, Schoeneberger TE, Ratts ET, Palmer ET, Samaha JK, Mance CJ, Muirhead EE. Short-term therapy of severe hypertension. Hemodynamic correlates of the antihypertensive response in man. Arch Intern Med. 1979;139:1233-1239.
10. Egan B, Schmouder R. The importance of hemodynamic considerations in essential hypertension. Am Heart J. 1988;116:594-599.
11. Northridge DB, Findlay IN, Wilson J, Henderson E, Dargie HJ. Noninvasive determination of cardiac output by Doppler echocardiography and electrical bioimpedance. Br Heart J. 1990;63:93-97.
12. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-988.
13. Ventura HO, Taler SJ, Strobeck JE. Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens. 2005;18:26S-43S.
14. Van De Water JM, Mount BE, Chandra KM, Mitchell BP, Woodruff TA, Dalton ML. TFC (thoracic fluid content): a new parameter for assessment of changes in chest fluid volume. Am Surg. 2005;71:81-86.
15. Treister N, Wagner K, Jansen PR. Reproducibility of impedance cardiography parameters in outpatients with clinically stable coronary artery disease. Am J Hypertens. 2005;18:44S-50S.
16. Van De Water JM, Miller TW. Impedance cardiography: the next vital sign technology? Chest. 2003;123:2028-2033.
17. Yung G, Fedullo P, Kinninger K, Johnson W, Channick R. Comparison of impedance cardiography to direct fick and thermodilution cardiac output determination in pulmonary arterial hypertension. Congest Heart Fail. 2004;10(2 suppl 2):7-10.
18. Defined Daily Dose (DDD) developed by the World Health Organization for use in drug utilization studies. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index With Defined Daily Doses (DDDs). Oslo, Norway: WHO Collaborating Centre; 2000.
19. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
21. Singh H, Johnson ML. Prescribing patterns of diuretics in multi-drug antihypertensive regimens. J Clin Hypertens. 2005;7:81-87.
22. Ubel PA, Jepson C, Asch DA. Misperceptions about β-blockers and diuretics: a national survey of primary care physicians. J Gen Intern Med. 2003;18:1060-1061.
23. Connors AF, Dawson NV, Shaw PK, Montenegro HD, Nara AR, Martin L. Hemodynamic status in critically ill patients with and without acute heart disease. Chest. 1990;98:1200-1206.
24. Fagard RH, Pardaens K, Staessen JA, Thijs L. Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. Hypertension. 1996;28:31-36.
25. Messerli FH, Garavaglia GE, Schmieder RE, Sundgaard-Riise K, Nunez BD, Amodeo C. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987;107:158-161.
26. Hinderliter A, Blumenthal J, Waugh R, Chilukuri M, Sherwood A. Ethnic differences in left ventricular structure: Relations to hemodynamics and diurnal blood pressure variation. Am J Hypertens. 2004;17:43-49.
27. Alfie J, Galarza C, Waisman G. Noninvasive hemodynamic assessment of the effect of mean arterial pressure on the amplitude of pulse pressure. Am J Hypertens. 2005;18:60S-64S.
28. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-1545.
29. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol. 2005;45:813-827.
30. Abdelhammed AI, Smith RD, Levy P, Smits GJ, Ferrario CM. Noninvasive hemodynamic profiles in hypertensive subjects. Am J Hypertens. 2005;18:51S-59S.
31. Bhalla V, Isakson S, Bhalla MA, Lin JP, Clopton P, Gardetto N, Maisel AS. Diagnostic ability of B-type natriuretic peptide and impedance cardiography: testing to identify left ventricular dysfunction in hypertensive patients. Am J Hypertens. 2005;18:73S-81S.
32. Mitchell A, Buhrmann S, Saez AO, Rushentsova U, Schafers RF, Philipp T, Nurnberger J. Clonidine lowers blood pressure by reducing vascular resistance and cardiac output in young, healthy males. Cardiovasc Drugs Ther. 2005;19:49-55.
33. Breithaupt-Grogler K, Gerhardt G, Lehmann G, Notter T, Belz GG. Blood pressure and aortic elastic properties-verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther. 1998;36:425-431.
34. Ashida T, Nishioeda Y, Kimura G, Kojima S, Kawamura M, Imanishi M, Abe H, Kawano Y, Yoshimi H, Yoshida K, Kuramochi M, Omae T. Effects of salt, prostaglandin, and captopril on vascular responsiveness in essential hypertension. Amer J Hypertens. 1989;2:640-642.
35. Sharman DL, Gomes CP, Rutherford JP. Improvement in blood pressure control with impedance cardiograph-guided pharmacologic decision making. Congest Heart Fail. 2004;10:54-58.
36. Sramek BB, Tichy JA, Hojerova M, Cervenka V. Normohemodynamic goal-oriented antihypertensive therapy improves the outcome (abstract). Amer J Hypertens. 1996;9:141A.
37. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.